SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : TATRADER GIZZARD STUDY--Stocks 12.00 or Less..... -- Ignore unavailable to you. Want to Upgrade?

To: nolimitz who wrote (56808)11/28/2006 4:21:09 PM
From: lexi2004  Read Replies (1) | Respond to of 59879
 
Did you keep some of your shares from before?

Lexi



To: nolimitz who wrote (56808)11/28/2006 4:43:02 PM
From: hotlinktuna  Read Replies (1) | Respond to of 59879
 
Wow! What a pop on DVAX...haven't traded it for quite some time...tuna



To: nolimitz who wrote (56808)11/29/2006 8:14:20 AM
From: joseffy  Read Replies (1) | Respond to of 59879
 
Dynavax Technologies (DVAX) shares are expected to jump after it reported statistically significant results of a Phase III trial comparing hepatitus B vaccine Heplisav to Glaxo's Energix-B vaccine.

(Dow Jones) By Steve Goldstein


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News